Observational studyTargeted oncology2023

Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.

Kenji Morimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.